Degarelix Injection 80mg

The clinical application of degarelix injection 80mg is mainly focused on the treatment of prostate cancer. Relying on its advantages of rapid androgen reduction and no initial flare effect, it covers different treatment stages of advanced, locally advanced, and recurrent prostate cancer, and can be used in combination with other therapeutic modalities according to patient conditions.

The core therapeutic goal for advanced or metastatic prostate cancer (including bone metastasis, lymph node metastasis, etc.) is to rapidly reduce androgen levels to the castrate level (<50ng/dL), block the nutrient supply of gonadal steroids to cancer cells, thereby controlling tumor progression and relieving clinical symptoms. As a first-line castration therapy, the product has become one of the preferred options for such patients due to the highly efficient absorption of the injectable formulation. Unlike traditional GnRH agonists, this injection does not require an initial stimulation phase followed by suppression.

After subcutaneous injection, it directly and competitively binds to pituitary GnRH receptors, rapidly inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and subsequently quickly reducing the synthesis and release of testicular androgen. Androgen levels are usually reduced to the castrate level within 24–48 hours after administration, with no transient androgen elevation (flare effect). This feature is particularly critical for advanced patients at risk of bone metastasis and spinal cord compression.

As it effectively avoids adverse events such as accelerated tumor progression and aggravated bone pain caused by androgen flare, significantly improving treatment safety.In clinical practice, for patients with advanced prostate cancer who cannot tolerate or refuse surgical castration, or who have comorbidities (e.g., cardiovascular disease, diabetes, etc.), it can serve as a long-term maintenance treatment. Regular subcutaneous injections sustainably control androgen levels, delay tumor progression, prolong patient survival, improve quality of life, and alleviate tumor-related symptoms such as bone pain, frequent urination, and urgency.

It effectively avoids adverse events such as accelerated tumor progression and bone pain caused by androgen flare, significantly improving treatment safety. Clinically, it serves as a long-term maintenance therapy for patients with advanced prostate cancer who are intolerant to or refuse surgical castration, or have comorbidities including cardiovascular diseases and diabetes. Regular subcutaneous injections can sustain androgen suppression, delay tumor progression, prolong survival, improve quality of life.

And relieve tumor-related symptoms such as bone pain, frequent urination and urinary urgency.Compared with traditional endocrine therapies, degarelix delivers faster efficacy onset and more stable hormonal suppression. It rapidly relieves various discomforts induced by tumor metastasis and greatly reduces the risk of acute complications. Its unique mechanism eliminates the risk of disease deterioration caused by androgen surge, making it ideal for the initial treatment of high-risk metastatic patients. Additionally, it exhibits low resistance during long-term administration and sustainably maintains castrate-level androgen to slow tumor progression. 

The treatment of locally advanced prostate cancer (tumor invasion beyond the prostatic capsule, seminal vesicles, and other surrounding tissues without distant metastasis) usually involves comprehensive therapy including surgery and radiotherapy. Degarelix injection 80mg can be used as an adjuvant treatment in combination with surgery or radiotherapy to enhance efficacy.For locally advanced patients who are unsuitable for surgical resection (e.g., large tumor volume, extensive invasion) or refuse surgery, the product can be used alone as long-term androgen deprivation therapy.

The 80mg maintenance dose via subcutaneous injection continuously suppresses androgen levels, shrinks the tumor, stabilizes the disease, prevents further invasion of surrounding tissues, and creates opportunities for subsequent treatment. For patients undergoing radiotherapy, combination with this injection significantly improves radiotherapy efficacy, as androgens reduce the sensitivity of prostate cancer cells to radiation. By rapidly and sustainably lowering androgen, the product enhances the response of cancer cells to radiotherapy, reduces radiotherapy resistance, and lowers the risk of local recurrence.

In addition, neoadjuvant therapy with the product before surgery for some locally advanced prostate cancer patients can rapidly reduce androgen levels via injection, leading to tumor shrinkage and downstaging, improving surgical resection rates.

Reducing the risk of tumor spread during surgery, and improving postoperative prognosis.This therapy features a standardized treatment schedule and high safety profile. Long-term maintenance treatment can continuously inhibit tumor proliferation and effectively consolidate the efficacy of surgery and radiotherapy. It reduces the recurrence of local lesions, delays disease progression, improves the radical cure rate for locally advanced patients, and optimizes long-term prognosis and quality of life.

Degarelix stably suppresses androgen levels without causing androgen surge, making it suitable for perioperative and radiotherapy-period treatment. With low administration frequency and favorable tolerability, it minimizes long-term adverse reactions, stabilizes local lesions, reduces progression and recurrence risks, and supports individualized comprehensive treatment for patients.

After radical prostatectomy or radiotherapy, some patients experience elevated prostate-specific antigen (PSA), indicating tumor recurrence, requiring re-initiation of endocrine therapy. It is an important option for second-line endocrine therapy.
For patients with PSA recurrence after surgery or radiotherapy without distant metastasis, the 80mg maintenance dose via subcutaneous injection effectively suppresses androgen and PSA levels, delays tumor progression, and prevents progression to metastatic prostate cancer.

For recurrent patients with distant metastasis, this injection can be combined with novel endocrine agents (e.g., enzalutamide, abiraterone, etc.) to further enhance efficacy and prolong progression-free survival.Furthermore, for recurrent patients who developed resistance to previous GnRH agonist therapy or could not tolerate agonist-related adverse reactions, switching to degarelix injection 80mg effectively improves treatment outcomes. Its mechanism of action differs from agonists, with no receptor desensitization, allowing sustained androgen inhibition and providing a new therapeutic direction for drug-resistant patients. 

Addressing the common clinical challenge of prostate cancer recurrence after surgery or radiotherapy, degarelix overcomes the limitations of traditional endocrine agents and resolves clinical problems such as resistance and intolerance to GnRH agonists. As a second-line therapeutic option, it provides stable and sustained androgen suppression to control recurrent lesions, continuously reduce PSA levels, and block tumor proliferation and distant metastasis.

With a favorable safety profile and no androgen surge-related deterioration, it is suitable for long-term individualized treatment. Its convenient monthly dosing improves patient adherence, avoids treatment interruption, consolidates second-line therapeutic effects, prolongs progression-free survival, optimizes overall prognosis, and serves as a safe and effective preferred remedy for recurrent prostate cancer.

The active ingredient of the product, degarelix, is a highly selective GnRH receptor antagonist, which is fundamentally different in mechanism from traditional GnRH agonists (e.g., leuprorelin, goserelin). Agonists first stimulate pituitary GnRH receptors, causing transient elevations in LH and FSH, followed by a temporary increase in androgen (flare effect), and only then does receptor desensitization occur to suppress androgen secretion. In contrast, degarelix directly and competitively binds to pituitary GnRH receptors without an initial stimulatory phase, immediately blocking the stimulatory effect of GnRH on the pituitary gland.

Rapidly inhibiting LH and FSH secretion, and thereby quickly reducing androgen levels.This unique mechanism leads to an extremely rapid onset of action after subcutaneous administration of it. androgen is typically reduced to castrate levels within 24 hours of dosing, with stable castration achieved within 48 hours, and no androgen flare occurs throughout treatment. This feature not only rapidly relieves tumor-related symptoms but also effectively prevents serious adverse events such as tumor progression, aggravated bone pain, and spinal cord compression caused by androgen flare. It is especially suitable for prostate cancer patients at risk of bone metastasis, significantly improving the safety and efficacy of treatment.

Unlike traditional GnRH agonists that cause initial hormonal fluctuations, degarelix adopts a direct blocking mode to fundamentally eliminate various clinical risks induced by hormone flare, making it particularly suitable for the initial intervention in high-risk, advanced and acute prostate cancer patients. It features stronger binding affinity with GnRH receptors, reversible and stable efficacy, and no receptor desensitization after long-term administration. It can precisely regulate the hypothalamic-pituitary-gonadal axis, maintain stable castrate androgen levels, and avoid recurrent disease fluctuations.

Additionally, it exerts minimal interference with the cardiovascular system and has mild and controllable adverse reactions, catering to long-term treatment for elderly patients or those with cardiovascular comorbidities. With the advantages of rapid onset, sustained stable hormonal inhibition and high safety, degarelix is recommended as a preferred endocrine therapy agent by domestic and international authoritative guidelines. It compensates for the shortcomings of traditional drugs, provides a safer and more efficient individualized treatment strategy for prostate cancer patients at different stages and risk levels.

The product is administered via subcutaneous injection, which causes less trauma and pain than intramuscular injection, resulting in better patient tolerance. The product is packaged in a prefilled syringe with an accurate dose (80mg per syringe) and requires no additional dilution. Medical staff can complete administration quickly, and patients may self-administer at home under professional guidance, greatly improving convenience and reducing hospital visits-particularly beneficial for long-term maintenance therapy.

In addition, it has a rational dosing schedule: a loading dose is given in the initial 28‑day phase, followed by one 80mg maintenance dose subcutaneously every 28 days. The low frequency avoids missed or interrupted doses from frequent administration, markedly improving treatment compliance. Subcutaneous injection also avoids gastrointestinal absorption interference seen with oral drugs, providing more stable absorption and ensuring sustained efficacy to maintain androgen within the castrate range.

The standardized dosing system of this preparation perfectly meets the long-term chronic disease management needs of prostate cancer patients and avoids the drawbacks of cumbersome operation and unstable absorption associated with traditional administration methods. The long-interval dosing regimen greatly reduces patients' medical burden, effectively prevents decreased compliance and treatment interruption during long-term therapy, and ensures the continuity and integrity of endocrine treatment.

Its stable drug absorption eliminates drastic fluctuations in blood drug concentration and prevents disease progression caused by failed hormone control. With a mild administration method, it delivers higher tolerability for elderly, frail patients and those with multiple underlying diseases, enabling standardized long-term treatment, ensuring long-term anti-tumor efficacy, and providing reliable pharmaceutical support for the whole-course standardized management of prostate cancer.